N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer-Reference-Cited by-同舟云学术

N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer

Published:2005-09 Issue:3 Volume:5 Page:211-213
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Alberts Steven R.,Sinicrope Frank A.,Grothey Axel

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference5 articles.

1. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study;Diaz Rubio;Proc Am Soc Clin Oncol,2005

2. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;Andre;N Engl J Med,2004

3. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

4. Why the epidermal growth factor receptor? The rationale for cancer therapy;Baselga;Oncologist,2002

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Informed Bayesian survival analysis;BMC Medical Research Methodology;2022-09-10

2. An Electronic Information Kiosk for Enhancing Patient Accrual for Cancer Clinical Trials: A Pilot and Feasibility Study;Cureus;2022-05-18

3. Early-Onset Colorectal Cancer: The Mystery Remains;JNCI: Journal of the National Cancer Institute;2021-08-18

4. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer;Clinical Gastroenterology and Hepatology;2020-11

5. Systemıc Chemotherapy in Colorectal Cancer;Colon Polyps and Colorectal Cancer;2020-10-30